Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Suzhou Zelgen Biopharmaceuticals

56 clinical trials

Clinical trial
A Multicenter, Randomized, Double-Blind,Placebo-controlled,Phase 2 Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase 1 Dose Escalation, Safety and Tolerability Study of Jaktinib in Patients With Primary Myelofibrosis (PMF) or Post-polycythemia Vera/Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) and Who Are Relapsed/ Refractory to a Marketed JAK Inhibitor
Status: Recruiting, Estimated PCD: 2025-05-31
Clinical trial
A Phase I/II Study Of The Efficacy,Safety and PharmacokineticsOf Jaktinib Hydrochloride Cream In Subjects With Mild To Moderate Atopic Dermatitis
Status: Completed, Estimated PCD: 2022-09-08
Clinical trial
A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers
Status: Completed, Estimated PCD: 2022-01-12
Clinical trial
A Phase 1 Dose Escalation and Expansion, Tolerability, Safety, Pharmacokinetics / Pharmacodynamics and Preliminary Efficacy Study of ZG0895.HCl in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase 1/2 Dose Escalation, Tolerability, Safety and Pharmacokinetics Study of ZG005 in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Jaktinib in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase I/II Dose Escalation Study to Evaluating the Tolerability, Safety, Efficacy and Pharmacokinetics of ZG2001 Tosilate Tablets in Participants With KRAS Mutated Advanced Solid Tumours
Status: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
Dose Escalation Study Of Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Jaktinib in Adult Patients With Severe Alopecia Areata
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase I Tolerance, Safety and Efficacy Study of Alkotinib in Patients With Advanced ALK Positive /ROS1 Positive NSCLC and Previously Treated With Chemotherapy or Crizotinib
Status: Completed, Estimated PCD: 2022-10-17
Clinical trial
A Phase 2 ,Safety and Efficacy Study of Jaktinib Hydrochloride Tablets for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase I/II Study Of The Efficacy,Safety and Pharmacokinetics Of Jaktinib Hydrochloride Cream In Subjects With Mild To Moderate Alopecia Areata
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase III Extended Clinical Trial of Long-term Safety and Efficacy of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase I/II Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For Recombinant Human Thyroid Stimulating Hormone In Post-thyroidectomized Patients
Status: Completed, Estimated PCD: 2020-12-29
Clinical trial
An Open, Single-arm, Self-controlled, Multi-center Phase 3 Study to Compare the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal
Status: Completed, Estimated PCD: 2023-07-05
Clinical trial
A Study to Evaluate the Effect of Oral Administration of Jaktinib Hydrochloride Tablets on QT/Corrected QT (QTc) Interval in Healthy Participants
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase I/II Dose Escalation and Expansion Study to Evaluating the Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase I/II Study to Evaluate Safety and Pharmacokinetics and Initial Efficacy of ZG005 in Combination With Paclitaxel Plus Cisplatin/Carboplatin ± Bevacizumab in Patients With Advanced Cervical Carcinoma
Status: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.
Status: Not yet recruiting, Estimated PCD: 2026-07-01
Clinical trial
Absorption, Distribution, Metabolism, and Excretion Study of [14C]-Jaktinib in Chinese Male Healthy Subjects(The Mass Balance and Biotransformation Study of [14C]-Jaktinib).
Status: Completed, Estimated PCD: 2022-01-30
Clinical trial
A Single-dose, Randomized, Open-label, Repeated Cross-over Pharmacokinetic Comparison Study of Two Formulations of Jaktinib Hydrochloride Tablets in Healthy Adult Volunteers Under Fasted Conditions
Status: Completed, Estimated PCD: 2023-12-20
Clinical trial
An Open-Label, Multicenter, Extension Study to Assess the Long-Term Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Study To Evaluate The Pharmacokinetics Of Jaktinib Hydrochloride Tablets In Subjects With Hepatic Impairment And Normal Hepatic Function
Status: Completed, Estimated PCD: 2022-09-19
Clinical trial
A Phase II, Multicenter, Single-arm Study to Evaluate Safety and Efficacy of Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib
Status: Terminated, Estimated PCD: 2022-10-11
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Study to Evaluate the Efficacy and Safety of Jaktinib Hydrochloride Tablets in Participants Receiving the Best Available Treatment for Severe Novel Coronavirus Pneumonia
Status: Withdrawn, Estimated PCD: 2024-04-23
Clinical trial
A Phase I Dose Escalation Study of Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by a Phase II Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
Status: Not yet recruiting, Estimated PCD: 2026-04-01
Clinical trial
A Multi-center, Open, Dose Exploration and Dose Expansion Phase I/II Study of ZG005 Combined With Donafenib Tosilate Tablets in Patients With Advanced Solid Tumor
Status: Not yet recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase I, Multicenter,Open-label,Dose-Escalation and Expansion Study of CS1001 in Combination With Donafenib in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase II Study To Evaluate The Efficacy And Safety of Jaktinib Hydrochloride Tablets In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment
Status: Completed, Estimated PCD: 2022-11-01
Clinical trial
A Multi-center, Open, Dose Exploration and Dose Expansion Phase I/II Clinical Study of Toripalimab（JS001） Combined With Donafenib in Patients With Advanced Hepatocellular Carcinoma
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Second Study to Assess the Efficacy and Safety of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia
Status: Not yet recruiting, Estimated PCD: 2025-02-01
Clinical trial
Efficacy and Safety of Donafenib in Patients With Previously Treated Metastatic Colorectal Cancer:a Controlled,Multicentre,Randomised, Phase 3 Trial
Status: Completed, Estimated PCD: 2020-04-30
Clinical trial
A Multicentric Phase I/II Study of Jaktinib Hydrochloride Tablets in Combination With Azacitidine for Injection in Patients With Myelodysplastic Syndromes(MDS) With Myelofibrosis(MF) or MDS/Myeloproliferative Neoplasms With MF
Status: Terminated, Estimated PCD: 2022-06-10
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study of Jaktinib Hydrochloride Tablets in the Treatment of Adult Patients With Moderate and Severe Atopic Dermatitis
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 1B Study of Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer
Status: Terminated, Estimated PCD: 2019-06-13
Clinical trial
A Phase 1/2 Dose Escalation Study of the Tolerability, Safety, Efficacy and Pharmacokinetics of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Study to Assess the Efficacy and Safety of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia
Status: Not yet recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase 1/2 Dose Escalation and Expansion Study of Donafenib Tosilate Tablets in Combination With KN046 Injection in Advanced Gastrointestinal Tumors
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Multi-center,Randomized,Double-blind,Placebo,Parallel-controlled Phase II Clinical Study of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis Patients
Status: Completed, Estimated PCD: 2022-05-19
Clinical trial
Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma：an Open-label,Phase 1 Study.
Status: Terminated, Estimated PCD: 2021-10-20
Clinical trial
A Phase 3, Stratified Randomized, Double-blind, Placebo-controlled Study of Topical Recombinant Human Thrombin (rhThrombin) in Surgical Hemostasis
Status: Completed, Estimated PCD: 2021-10-20
Clinical trial
A Phase Ⅱ Study to Evaluate the Safety and Efficacy of Jaktinib Hydrochloride Tablets in the Treatment of Severe Alopecia Areata.
Status: Completed, Estimated PCD: 2021-11-26
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo, Parallel-controlled Phase Ⅱ Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Patients With Active Ankylosing Spondylitis
Status: Completed, Estimated PCD: 2022-08-02
Clinical trial
A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of Jaktinib in Adult Patients With Moderate to Severe Alopecia Areata
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Dose-escalated Phase Ⅰ Trial to Assess the Tolerance and Pharmacokinetics of Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML Patient
Status: Terminated, Estimated PCD: 2022-02-09
Clinical trial
A Randomized, Double-blind, Double-simulated, Parallel-controlled, Multicenter Phase III Study Evaluating the Efficacy and Safety of Jaktinib Versus Hydroxycarbamide in Patients With Intermediate-2 or High-risk Myelofibrosis
Status: Completed, Estimated PCD: 2023-10-18
Clinical trial
A Phase 2,Multi-center, Open-label Study Evaluating Safety and Efficacy of Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.
Status: Completed, Estimated PCD: 2021-02-02
Clinical trial
A Phase I/II Dose Escalation, Tolerability, Safety, Pharmacokinetics and Multiple Cohort Expansion Study of ZGGS18 in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Phase II Study of the Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Phase 1 Dose Escalation, Tolerability, Safety and Pharmacokinetics Study of ZGGS15 in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase 1B Study of Donafenib Monotherapy in Advanced Oesophageal Cancer Progressing After Chemotherapy
Status: Terminated, Estimated PCD: 2020-10-29
Clinical trial
Jaktinib in Intermediate-risk and High-risk Myelofibrosis and Previously Treated With Ruxolitinib
Status: Completed, Estimated PCD: 2022-08-03
Clinical trial
A Randomized, Open-label, Multi-center, Controlled Phase Ⅲ Study to Evaluate the Safety and Efficacy of Recombinant Human Thryoid Stimulating Hormone（rhTSH） for Adjuvant Radioiodine Ablation Therapy in Postoperative Patients With Differentiated Thyroid Cancer
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase I Dose Escalation Study of Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by a Phase II Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
Status: Not yet recruiting, Estimated PCD: 2026-05-01